DLBCL-Type Richter Transformation Associated With Worse Prognosis vs DLBCL
The development of aggressive lymphoma, typically DLBCL, in patients initially diagnosed with CLL is the defining characteristic of Richter transformation.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
Chronic Lymphocytic Leukemia Treatment Decision Making With Venetoclax-Based Therapy
A review of case studies that outline treatment decisions based on patient and disease characteristics.
Hairy Cell Leukemia: Cladribine With Concurrent Rituximab May Improve Outcomes
Rituximab has some single-agent activity in HCL, but there is evidence that it may eliminate MRD when used with cladribine or pentostatin.
CAR-NK Cells Make Their Debut in Hematologic Cancers
The new type of adoptive cell therapy showed a response in 8 of 11 patients with hematologic malignancies in a clinical study.
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL
Due to the possibility of loss of CD19 expression following treatment with a single CD19-targeted approach, patients may become ineligible for the alternative approach.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Induction in Transplant-Eligible Mantle Cell Lymphoma With Rituximab and Cytarabine Added to Rituximab and Bendamustine
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
Brentuximab Vedotin With Bendamustine for Patients With Refractory or Multiple Relapsed Classic Hodgkin Lymphoma
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Glyphosate Exposure and Relative Risks of Non-Hodgkin Lymphoma or Multiple Myeloma
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Expert Opinion on Addressing Psychosocial Needs of Children Receiving CAR-T Therapy
The authors of this article emphasized the importance of actively involving a diverse group of interdisciplinary team members in the psychosocial care of these patients.
Large Consortium Study Reveals More Details on the Link Between Viruses and Cancer
Researchers use whole-genome and whole-transcriptome sequencing data to reveal viral sequences in cancer tissue.
Increased Risk of Venous Thromboembolism in Patients With Myelofibrosis
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.
Evidence for Increased DNA Methylation Heterogeneity in Certain Circulating CLL Cells
In this study, epigenetic heterogeneity was not associated with the birth rate of leukemic cells.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Psoriasis Linked to Increased Risk for Developing Cancer
Increased risk particularly seen with keratinocyte cancer and lymphomas.
Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
An Early Look at When CAR-T Therapy Fails Patients With CLL
A study showed how long patients with CLL may live after CAR-T therapy failure, providing a benchmark for trials evaluating therapies in the post–CAR-T setting.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
